Lexaria Bioscience (LEXX) Net Equity Issued and Repurchased (2016 - 2026)

Lexaria Bioscience has reported Net Equity Issued and Repurchased for 10 years, with the latest figure at $3.0 million in Q1 2026.

• Quarterly Net Equity Issued and Repurchased rose 25873.16% year-over-year to $3.0 million in Q1 2026, while the trailing twelve-month figure through May 2026 was $6.5 million (changed N/A YoY) and the FY2025 annual result came in at $6.0 million, up 43.66% from the prior year.
• Net Equity Issued and Repurchased retreated to $3.0 million in Q1 2026 per LEXX's latest filing, from $3.5 million in the prior quarter.
• Over five years, Net Equity Issued and Repurchased peaked at $4.3 million in Q4 2024 and troughed at -$121687.0 in Q3 2023.
• A 4-year average of $2.0 million and a median of $2.1 million in 2023 frame the typical range for Net Equity Issued and Repurchased.
• The sharpest annual moves came in 2025 and 2026: Net Equity Issued and Repurchased slipped 20.05% in 2025, then soared 25873.16% in 2026.
• Over 4 years, Net Equity Issued and Repurchased stood at $1.2 million in 2023, then surged by 248.27% to $4.3 million in 2024, then declined by 20.05% to $3.5 million in 2025, then dropped by 12.38% to $3.0 million in 2026.
• According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $3.0 million, $3.5 million, and $11720.0 for Q1 2026, Q4 2025, and Q1 2025 respectively.